abstract |
The present invention relates to the use of ALK tyrosine-kinase receptor inhibitors, in particular Alectinib, and compositions including it, as senolytic drug. In particular it relates to the use as senolytic drugs in a method of treatment of tumour or other pathological and incapacitating conditions associated to the cellular senescence. |